Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Overview status: Source-reviewed overview
What does this software do?Authorized purpose: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Pulmonary nodules in the thorax, including solid and subsolid (part-solid and ground-glass) nodules. Input: Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.
Who uses it?Intended users: Radiologists and trained professionals evaluating the CAD output.
What does the software produce?Output: A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
What is its most important limitation?Key limitation: Validated nodule scope is solid nodules at least 3 mm and less than 30 mm and subsolid nodules at least 5 mm and less than 30 mm, including central or peripheral and round or irregular contours. Intravenous contrast is not established as a supported characteristic in the study comparison; the packet states full radiologist review remains required and the hosting application supplies the user interface.
Clinical takeaway
Clinical role: Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Evidence takeaway
Evidence from the reviewed source record: The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Adjunctive CAD assistance to alert radiologists to regions of interest that may otherwise be overlooked during chest MDCT review; concurrent first-reader or second-reader use is permitted, followed by full radiologist review.
Concurrent first-reader support followed by full review, or second-reader support after the radiologist's initial read; the algorithm alerts to ROI candidates and does not provide its own display UI.
Chest MDCT from multivendor scanners, with 16 or more detector rows; the scan must cover the entire thorax from lung apices to bases, with cranio-caudal or caudal-cranial direction, 100-140 kVp, up to and including 2.5 mm slice thickness, and no reconstruction gaps. The packet describes Siemens, GE, Philips, and Toshiba scanner data and typical validated kernels.
A list of nodule candidate locations sent to a visualization application or rendering component, which generates output image series with CAD marks superimposed on the input thoracic CT images.
Validated nodule scope is solid nodules at least 3 mm and less than 30 mm and subsolid nodules at least 5 mm and less than 30 mm, including central or peripheral and round or irregular contours. Intravenous contrast is not established as a supported characteristic in the study comparison; the packet states full radiologist review remains required and the hosting application supplies the user interface.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The algorithm sends candidate locations to a hosting visualization application such as syngo MM Oncology or a rendering component; syngo MM Oncology is deployed on syngo.via, which displays the CAD marks. The device has no standalone UI, and specific local PACS or RIS compatibility is not established.
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Training and support
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-09
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring and change control
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-09
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for syngo.CT Lung CAD; FDA labeling remains controlling for clinical use, limitations, and performance.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The pivotal retrospective reader study had 20 readers review all 232 cases in both second-reader and concurrent-first-reader workflows; five expert radiologists reviewed consolidated marks. Reader-majority truthing with expert adjudication identified 143 cases with at least one true nodule and 89 without true nodules. All reported analysis endpoints were satisfactorily met and all readers showed significant improvement in detection of solid, part-solid, and ground-glass nodules in both workflows; no numeric sensitivity, specificity, AUC, PPV, NPV, or reader-delta result is provided in the packet text.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-09
No public price or quote for the exact K203258 configuration was established in this review.
Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-09
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203258. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Verify pricing and total cost: No public price or quote for the exact K203258 configuration was established in this review.
Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
17Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history7 sources - 3 history items
Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for...
Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making...
Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.